|Drug Patent Number||Company||Drug Patent Title||Drug Patent Expiry||Activity Alert|
|These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.|
|US6335447||FERRER INTERNACIONAL||Quinolonecarboxylic acid derivatives or salts thereof|| |
(a month from now)
|These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).|
|US9399014||FERRER INTERNACIONAL||Pharmaceutical topical compositions|| |
(6 years from now)
|US9180200||FERRER INTERNACIONAL||Pharmaceutical topical compositions|| |
(8 years from now)
Xepi is owned by Ferrer Internacional.
Xepi contains Ozenoxacin.
Xepi has a total of 3 drug patents out of which 0 drug patents have expired.
Xepi was authorised for market use on 11 December, 2017.
Xepi is available in cream;topical dosage forms.
Xepi can be used as treatment of impetigo due to staphylococcus aureus or streptococcus pyogenes.
Drug patent challenges can be filed against Xepi from 2021-12-11.
The generics of Xepi are possible to be released after 29 January, 2032.
|Drug Exclusivity||Drug Exclusivity Expiration|
|New Chemical Entity Exclusivity (NCE)||Dec 11, 2022|
NCE-1 date: 2021-12-11
Market Authorisation Date: 11 December, 2017
Treatment: Treatment of impetigo due to staphylococcus aureus or streptococcus pyogenes
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic